Treatment Patterns and Visual Outcomes in Proliferative Macular Telangiectasia Type 2

Authors

• Maya Samman
• Kensington Hatcher
• Lydia Sauer, Corewell Health East
• Samuel Minaker
• Srinivas Kondapalli

Document Type

Conference Proceeding

Publication Date

6-2026

Publication Title

Investigative Ophthalmology and Visual Science

Abstract

Purpose : Macular Telangiectasia (MacTel) type 2 is a bilateral neurodegenerative macular disease characterized by parafoveal capillary telangiectasias, retinal cavitation, and outer retinal atrophy. In its proliferative stage, subretinal neovascularization (CNV) can further threaten central vision. While anti-vascular endothelial growth factor (VEGF) therapy is widely used to manage CNV in MacTel type 2, real-world data on visual trajectories, treatment burden, and recurrence patterns remain limited. The purpose of this study was to examine real-world treatment patterns and outcomes of patients with CNV secondary to MacTel type 2. Understanding these parameters could help optimize surveillance and treatment strategies.

Methods : A retrospective chart review was conducted of clinical notes and optical coherence tomography (OCT) images from patients with proliferative MacTel type 2 who received anti-VEGF intravitreal injection. All patients had Snellen visual acuity testing and OCT at baseline and each subsequent follow-up. Patients were treated until CNV resolution. Descriptive statistics were used to summarize demographic and clinical characteristics of the cohort.

Results : A total of 22 eyes (17 patients) were analyzed. The mean age at CNV diagnosis was 63.8 years, and 58.8% of patients were female. The mean number of anti-VEGF injections was 2.8 until CNV resolution. 8 eyes received bevacizumab, 6 eyes received aflibercept, 5 eyes received ranibizumab, and 2 received combination therapy. The median BCVA was 20/40 before CNV diagnosis, 20/60 at diagnosis, and 20/50 at resolution. The mean central macular thickness (CMT) was 250.5 µm before CNV diagnosis, 271.1 µm at diagnosis, and 227.1 µm at resolution. Recurrence of CNV occurred in 7 of 22 eyes (31.8%) at a mean of 10 months following initial resolution.

Volume

67

Issue

7

First Page

1940

Comments

Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, May 3-7, 2026, Denver, CO

Last Page

1940

Recommended Citation

Samman M, Hatcher K, Sauer L, Minaker S, Kondapalli S. Treatment patterns and visual outcomes in proliferative macular telangiectasia type 2. Invest Ophthalmol Vis Sci. 2026 Jun;67(7):1940.